← Back to all trials
Recruiting
NCT06976918
Research Platform Myelofibrosis and Anemia
Conditions: Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Anemia, Myelofibrosis; Anemia, Myelofibrosis
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 200
Sponsor: iOMEDICO AG
Location: Multiple sites all over Germany Multiple Locations
Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.
Eligibility Criteria
Inclusion Criteria:
* Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).
* Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.
* Start of first or subsequent systemic treatment for MF.
* Informed consent and registration for the GSG-MPN Bioregistry.
* Willingness and capability to participate in PRO assessment.
* Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.
Exclusion Criteria:
* No systemic therapy for diagnosed primary or secondary MF.
* Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.
Source: ClinicalTrials.gov (NCT06976918). StuddyBuddy aggregates publicly available trial information.
